
Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions
FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection
BURLINGTON, N.C., April 23, 2025 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments.
'Labcorp is dedicated to providing oncologists with a comprehensive portfolio of innovative solutions that enable precise, timely and personalized treatment decisions,' said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. 'With the expansion of our portfolio to include Labcorp Plasma Detect for clinical use and the availability of PGDx elio plasma focus Dx to support patient treatment selection, we're advancing care across the oncology spectrum, solidifying our commitment to transforming cancer diagnostics and improving patient outcomes.'
Labcorp Plasma Detect: Advanced Risk Assessment for Colon Cancer PatientsStage III colon cancer has a nearly 30% recurrence rate within five years. Labcorp Plasma Detect is a blood-based test using whole-genome sequencing (WGS) to detect circulating tumor DNA (ctDNA), indicating the presence of molecular residual disease (MRD).i Patients who are MRD-positive after cancer treatment have a higher risk of recurrence and a poorer prognosis. Labcorp's test detects cancer recurrence risk that conventional methods might miss, helping to identify patients who could benefit from additional treatment or therapy.
Key Features of Labcorp Plasma Detect:
The test is Labcorp's first tumor-informed MRD solution for clinical use to support recurrence risk stratification. Labcorp Plasma Detect launched in 2024 for biopharma use to support exploratory and investigational studies.
The test combines a WGS approach, without the need for a bespoke panel, with proprietary bioinformatics to deliver ctDNA detection down to a limit of detection (LOD95) of 0.005%.
Results are available approximately 14 days after Labcorp receives the initial sample, and seven days for subsequent monitoring time points for each patient.
Labcorp Plasma Detect is currently being evaluated in more than 10 clinical studies in the U.S. and internationally to assess MRD across various cancer types.
Labcorp Plasma Detect will be offered initially through an Early Experience Program, with the intent to expand availability more broadly.
PGDx elio plasma focus Dx Now Available for Use to Aid in Treatment SelectionPGDx elio plasma focus Dx is the first and only kitted pan-solid tumor liquid biopsy test to receive De Novo authorization from the FDA. This assay provides oncologists with a validated tool to assess various solid tumors for targeted treatment selection – all from a simple blood draw.
Key Features of PGDx elio plasma focus Dx:
The kitted model allows clinical laboratories and hospitals to retain control over patient specimens and data for research, care management and other clinical purposes.
As an FDA-authorized assay, PGDx elio plasma focus Dx requires only on-site verification – as opposed to a full validation – enabling more rapid implementation.
Once implemented, this rapid, scalable liquid biopsy genomic test provides actionable findings within a 4-to-5-day turnaround time, from isolated nucleic acid to variant report.
As part of the PGDx elio platform, the kitted model is compatible with FDA-cleared PGDx elio™ tissue complete, enabling seamless, in-house tissue-to-liquid reflexing and efficient comprehensive genomic profiling workflows.
Labcorp at the American Association for Cancer Research (AACR) 2025 Annual MeetingLabcorp will present key studies at the AACR 2025 Annual Meeting, including the clinical use of Labcorp Plasma Detect and performance of PGDx elio plasma focus Dx.
To learn more, or to connect with Labcorp at AACR in Chicago, visit https://oncology.labcorp.com/american-association-cancer-research-annual-meeting-2025
For more information about Labcorp's Oncology solutions, contact us at https://oncology.labcorp.com/contact-us
About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.
i The term MRD is often used interchangeably between molecular residual disease and minimal residual disease. Labcorp Plasma Detect detects molecular residual disease, which is defined as the subclinical presence of a cancer-associated biomarker indicating a high risk of recurrence, which cannot be detected by standard imaging techniques. MRD terminology is in accordance with the BLOODPAC Consortium.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
36 minutes ago
- Malaysian Reserve
InventHelp Inventor Develops New Type of Mirror (MHO-501)
PITTSBURGH, July 25, 2025 /PRNewswire/ — 'I wanted to create a specially designed mirror to simplify hairstyling tasks,' said an inventor, from Baker, La., 'so I invented THE STYLING COMPANION. My design eliminates the hassle of holding a mirror in one hand while styling with the opposite hand.' The invention provides a specially designed mirror for viewing the back of the head when cutting or styling hair. In doing so, it increases visibility, and it eliminates the need to hold a traditional handheld mirror. It also would keep hairstyling implements and essentials within easy reach. The invention features an adjustable and multi-functional design that is easy to use and move so it is ideal for stylists, barbers, households, etc. The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 24-MHO-501, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at


Malaysian Reserve
2 hours ago
- Malaysian Reserve
InventHelp Inventor Develops Modified Bra for Storing Items (MBQ-647)
PITTSBURGH, July 25, 2025 /PRNewswire/ — 'I wanted to create a better way to carry money, identification, keys, and other valuables within a bra,' said an inventor, from Rochester, N.Y., 'so I invented the ZIP BRA. My design provides added comfort, convenience, protection, and peace of mind for women.' The invention provides an improved design for a bra. In doing so, it offers a safe way to store or hold items such as a credit card, money, etc. As a result, it helps prevent irritation and other issues associated with storing items directly within the bra cup. It also eliminates the need to carry such items within a purse. The invention features a discreet design that is easy to wear and use so it is ideal for women. Additionally, it is producible in design variations. The original design was submitted to the Manhattan sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 24-MBQ-647, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at


Malaysian Reserve
2 hours ago
- Malaysian Reserve
AF 5.0: With AF5.0 Logic Maps, Strategy Architecture Becomes Actionable
NEW YORK, July 25, 2025 /PRNewswire/ — AF 5.0 has launched Logic Maps, a transformative visual module designed to make strategy development more intuitive, traceable, and explainable. This new feature displays each component of a strategy—conditions, filters, scoring mechanisms, signal paths—in a structured, node-based diagram that updates in real time. Unlike traditional rule-based editors, where logic is often hidden behind nested layers of conditions and syntax, AF5.0 Logic Maps allow users to see their strategies as systems, built from interconnected decisions and flows. This not only aids comprehension but drastically improves debugging, instruction, and version control. Key capabilities include: Live Node Structure: Users can view their entire strategy blueprint—entry and exit logic, scoring layers, filters, and alerts—on one interactive map. Each node is clickable and editable. Layered Visibility: Different types of logic (such as condition sets, scoring factors, and behavioral triggers) are organized into adjustable layers, so users can isolate sections for detailed work or zoom out for a strategic overview. Conflict Detection: Logic Maps automatically detect conflicting branches, circular dependencies, and broken paths, then highlight them visually for correction. Collaborative View Mode: Teams can comment on nodes, trace logic authorship, and compare map versions during review. Educators can also export maps with markup for feedback or grading. Presentation-Ready Export: Users can generate static or interactive versions of the Logic Map for use in pitch decks, classroom materials, or compliance documentation. 'Strategies are no longer just something you code—they're something you show, share, and refine visually,' said Marcus Leighton, Head of Product Strategy at AF 5.0. 'With AF5.0 Logic Maps, we've given users the power to explain their thinking clearly—whether to themselves, their teams, or their students.' Early adopters in institutional learning environments report significant gains in student comprehension and strategy quality after introducing Logic Maps into their curriculum. Instructors say the diagrams help learners avoid common design mistakes and better internalize systematic thinking. AF5.0 plans to extend Logic Maps with AI-suggested optimization paths and error probability markers in future versions. Current users can already sync the tool with Report Studio and Training Mode for a complete end-to-end strategy design and education loop. About AF 5.0 AF 5.0 is a visual-first platform for designing, testing, and explaining algorithmic strategies. It supports both individual learners and institutional teams through modular logic builders, real-time diagnostics, education tools, and structured visual layers. With AF 5.0, strategy development becomes more transparent, collaborative, and intelligent. ContactPR ManagerAutumn ReedAF 5.0service@ Photo – –